RC220 Human Ethics Approvals Received in Hong Kong
| Stock | Race Oncology Ltd (RAC.ASX) |
|---|---|
| Release Time | 10 Jul 2025, 9:07 a.m. |
| Price Sensitive | Yes |
Race Oncology Receives Hong Kong Ethics Approvals for RC220 Trial
- Prince of Wales Hospital and Queen Mary Hospital in Hong Kong receive approval to participate in Race's Phase 1 clinical trial of RC220
- Formal Department of Health approval expected in coming weeks, enabling patient recruitment to begin
- Trial designed to assess safety, tolerability and pharmacokinetics of RC220 alone and in combination with doxorubicin
Race Oncology Ltd has announced that the Prince of Wales Hospital and Queen Mary Hospital in Hong Kong have received Human Research Ethics Committee (HREC) approval to participate in the company's Phase 1 clinical trial of RC220 in combination with doxorubicin (RAC-010). This follows previous HREC approvals received for trial sites in Australia. Formal approval from the Hong Kong Department of Health (DoH) has been received for the Queen Mary Hospital, and is expected for the Prince of Wales Hospital in the coming weeks. Once site activations are complete in late July/mid-August 2025, patient recruitment can begin. The RAC-010 trial is designed to assess the safety, tolerability and pharmacokinetics of RC220 alone and in combination with doxorubicin, in patients with solid tumours. The principal investigators at the Hong Kong hospitals, Dr Herbert Loong and Dr Roland Ching-Yu Leung, expressed enthusiasm for the trial, highlighting the potential for RC220 to provide cardiac protection and enhanced efficacy when used with doxorubicin. Race's Vice President of Medical, Dr Simon Fisher, thanked the investigators for their support and looked forward to the teams working together in the coming months. The expansion of the trial to Hong Kong is expected to enable faster patient recruitment, as well as provide early clinical evidence of safety and efficacy in the East Asian pharmaceutical market.
Race Oncology is advancing the reformulated bisantrene (RC220) to address unmet needs of patients across multiple oncology indications, with a focus on anthracycline combinations, aiming to deliver cardioprotection and enhanced anticancer activity in solid tumours. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.